High Short Interest Snapshot
Capricor Therapeutics (CAPR) remains a focal point for short sellers, with short interest currently sitting at 33.9% of shares outstanding. According to the latest settlement data, 19.7 million shares are held short, placing the stock above the 98th percentile of tracked names. While this represents a slight decline from the 38.2% reported in late August, the position remains significantly elevated.
Market Context and Borrow Costs
Investors should note that the days-to-cover ratio is currently elevated at 5.9, suggesting that any sudden price volatility could lead to significant liquidity challenges for those looking to cover positions. The current borrow fee for CAPR is reported at 4.5%. With a cash runway of approximately 20.3 months and a 83% increase in shares outstanding over the last two years, the fundamental backdrop remains complex for both long and short participants. This data reflects the official bi-monthly settlement figures, which serve as a snapshot of open positions rather than daily trading flow.
Signal data sourced from CurvedTrading. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.